{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-05T09:58:55.135736+00:00","company":{"ticker":"OCGN","cik":1372299,"company_name":"Ocugen, Inc."},"pagination":{"limit":100,"returned":21,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"executive_change","fact_key":"63cca38e60","cik":1372299,"ticker":"OCGN","company_name":"Ocugen, Inc.","filed_at":"2026-06-03T20:30:32+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2026-06-03","interim":false,"role":"principal accounting officer","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Rita Johnson-Greene was appointed as principal accounting officer at Ocugen, Inc..","evidence_excerpt":"on June 3, 2026, Rita Johnson-Greene, MBA, the Company’s Chief Financial Officer, was appointed as the Company’s principal accounting officer.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-26-070124","anchor_url":"https://secwatch.observer/filing/0001104659-26-070124#claim-63cca38e60","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1372299/000110465926070124/0001104659-26-070124-index.htm"},{"fact_type":"executive_change","fact_key":"0543aa31fa","cik":1372299,"ticker":"OCGN","company_name":"Ocugen, Inc.","filed_at":"2026-06-03T20:30:32+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2026-05-29","interim":false,"role":"Chief Accounting Officer","role_category":"other_named_officer","successor_name":"Rita Johnson-Greene","successor_named":true},"claim":"Ramesh Ramachandran resigned as Chief Accounting Officer at Ocugen, Inc..","evidence_excerpt":"Effective May 29, 2026, Ramesh Ramachandran, CPA, MBA, CMA, resigned as the Chief Accounting Officer of Ocugen, Inc.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-26-070124","anchor_url":"https://secwatch.observer/filing/0001104659-26-070124#claim-0543aa31fa","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1372299/000110465926070124/0001104659-26-070124-index.htm"},{"fact_type":"executive_change","fact_key":"803e731a80","cik":1372299,"ticker":"OCGN","company_name":"Ocugen, Inc.","filed_at":"2026-05-14T20:31:51+00:00","payload":{"action":"separated","action_category":"departure","departure_tone":"not_disclosed","effective_date":"2026-05-08","interim":false,"role":"Chief Medical Officer","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Huma Qamar departed as Chief Medical Officer at Ocugen, Inc..","evidence_excerpt":"Effective May 8, 2026, Huma Qamar, M.D., MPH, CMI, separated from Ocugen, Inc. (the “Company”) as its Chief Medical Officer.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-26-061241","anchor_url":"https://secwatch.observer/filing/0001104659-26-061241#claim-803e731a80","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1372299/000110465926061241/0001104659-26-061241-index.htm"},{"fact_type":"debt_financing","fact_key":"5aa60461a2ca1b88c691a66c46df023babcc64c7","cik":1372299,"ticker":"OCGN","company_name":"Ocugen, Inc.","filed_at":"2026-05-14T20:30:23+00:00","payload":{"counterparty":"U.S. Bank Trust Company, National Association","effective_date":"2026-05-14","event":"incurrence","instrument_type":"convertible_notes","interest_rate_text":"6.75%","item_codes_triggered":["2.03"],"maturity_text":"due 2034","principal_text":"$15.0 million aggregate principal amount"},"claim":"Ocugen, Inc. incurred convertible notes of $15.0 million aggregate principal amount with U.S. Bank Trust Company, National Association at 6.75% maturing due 2034.","evidence_excerpt":"On May 14, 2026, the Company issued an additional $15.0 million aggregate principal amount of notes (the \"additional notes\") pursuant to the exercise in full of the over-allotment option granted by the Company to the initial purchaser in the offering.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-26-061230","anchor_url":"https://secwatch.observer/filing/0001104659-26-061230#claim-5aa60461a2ca1b88c691a66c46df023babcc64c7","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1372299/000110465926061230/0001104659-26-061230-index.htm"},{"fact_type":"debt_financing","fact_key":"ab00017723e4f4b50ba676e88de8b638e9a47724","cik":1372299,"ticker":"OCGN","company_name":"Ocugen, Inc.","filed_at":"2026-05-07T23:59:59+00:00","payload":{"counterparty":"U.S. Bank Trust Company, National Association","effective_date":"2026-05-07","event":"incurrence","instrument_type":"convertible_notes","interest_rate_text":"6.75%","item_codes_triggered":["2.03"],"maturity_text":"May 15, 2034","principal_text":"$115.0 million"},"claim":"Ocugen, Inc. incurred convertible notes of $115.0 million with U.S. Bank Trust Company, National Association at 6.75% maturing May 15, 2034.","evidence_excerpt":"On May 7, 2026, Ocugen, Inc. (the “Company”) completed its previously announced private offering (the “offering”) of $115.0 million aggregate principal amount of 6.75% Convertible Senior Notes due 2034 (the “notes”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-26-057138","anchor_url":"https://secwatch.observer/filing/0001104659-26-057138#claim-ab00017723e4f4b50ba676e88de8b638e9a47724","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1372299/000110465926057138/0001104659-26-057138-index.htm"},{"fact_type":"material_agreement","fact_key":"080953ff4d0121ab70647454457875ce7383f795","cik":1372299,"ticker":"OCGN","company_name":"Ocugen, Inc.","filed_at":"2026-05-07T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Indenture","agreement_type":"notes_offering","counterparty":"U.S. Bank Trust Company, National Association","effective_date":"2026-05-07","item_codes_triggered":["1.01"],"value_text":"$115.0 million aggregate principal amount of 6.75% Convertible Senior Notes due 2034"},"claim":"Ocugen, Inc. entered into Indenture with U.S. Bank Trust Company, National Association valued at $115.0 million aggregate principal amount of 6.75% Convertible Senior Notes due 2034 (effective 2026-05-07).","evidence_excerpt":"On May 7, 2026, Ocugen, Inc. (the “Company”) completed its previously announced private offering (the “offering”) of $115.0 million aggregate principal amount of 6.75% Convertible Senior Notes due 2034 (the “notes”). The notes were issued pursuant to an indenture, dated May 7, 2026 (the “Indenture”), between the Company and U.S. Bank Trust Company, National Association, as trustee.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-26-057138","anchor_url":"https://secwatch.observer/filing/0001104659-26-057138#claim-080953ff4d0121ab70647454457875ce7383f795","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1372299/000110465926057138/0001104659-26-057138-index.htm"},{"fact_type":"earnings_release","fact_key":"c87151e6c03eed4a7668845a844b8bf31015fd0e","cik":1372299,"ticker":"OCGN","company_name":"Ocugen, Inc.","filed_at":"2026-05-05T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"quarter ended March 31, 2026","report_date":"2026-05-05","result_type":"reported_results","revenue_text":null},"claim":"Ocugen, Inc. reported financial results for quarter ended March 31, 2026.","evidence_excerpt":"On May 5, 2026, Ocugen, Inc (the “Company”) issued a press release announcing certain financial results for the quarter ended March 31, 2026.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-26-055411","anchor_url":"https://secwatch.observer/filing/0001104659-26-055411#claim-c87151e6c03eed4a7668845a844b8bf31015fd0e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1372299/000110465926055411/0001104659-26-055411-index.htm"},{"fact_type":"material_agreement","fact_key":"07be7b1eacd9941be244a1a35837a9da1b41ed4e","cik":1372299,"ticker":"OCGN","company_name":"Ocugen, Inc.","filed_at":"2026-01-21T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Underwriting Agreement","agreement_type":"underwriting","counterparty":"Oppenheimer & Co. Inc.","effective_date":"2026-01-20","item_codes_triggered":["1.01"],"value_text":"15,000,000 shares of common stock at $1.50 per share, net proceeds approximately $20.8 million"},"claim":"Ocugen, Inc. entered into Underwriting Agreement with Oppenheimer & Co. Inc. valued at 15,000,000 shares of common stock at $1.50 per share, net proceeds approximately $20.8 million (effective 2026-01-20).","evidence_excerpt":"On January 20, 2026, Ocugen, Inc. (the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with Oppenheimer & Co. Inc. (the “ Underwriter ”), pursuant to which the Company agreed to issue and sell to the Underwriter, in an offering (the “ Offering ”) 15,000,000 shares of the Company’s common stock, par value $0.01 per share (the “ Common Stock ”), at an offering price of $1.50 per share (the “ Offering Price ”).","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-26-005454","anchor_url":"https://secwatch.observer/filing/0001104659-26-005454#claim-07be7b1eacd9941be244a1a35837a9da1b41ed4e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1372299/000110465926005454/0001104659-26-005454-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"144d4ca7422226ba23bb821d4c37639e6ea6b907","cik":1372299,"ticker":"OCGN","company_name":"Ocugen, Inc.","filed_at":"2025-07-01T23:59:59+00:00","payload":{"company_response":null,"compliance_status":"extension_granted","cure_deadline":"2025-12-29","deficiency_type":"minimum_bid_price","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":null,"notice_date":"2025-07-01","notice_type":"extension_granted","plan_due_date":null,"raw_rule_text":null,"reported_value":null,"rule_numbers":["5550(a)(2)","5810(c)(3)(A)"],"rules_cited_in_text":true},"claim":"Ocugen, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).","evidence_excerpt":"July 1, 2025, Ocugen, Inc.\n(the “Company”) received a written notice (the “Notice”) from the Listing Qualifications Department (the “Staff”)\nof the Nasdaq Stock Market (“Nasdaq”) that the Company has been granted an additional 180 calendar days, or until December\n29, 2025, to regain compliance with the minimum closing bid price of $1.00 per share (the “Minimum Bid Price Requirement”)\nas required by Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. As previously reported, on\nDecember 31, 2024, Nasdaq notified the Company that for the last 30 consecutive business","confidence":0.98,"filing_url":"https://secwatch.observer/filing/0001104659-25-064695","anchor_url":"https://secwatch.observer/filing/0001104659-25-064695#claim-144d4ca7422226ba23bb821d4c37639e6ea6b907","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1372299/000110465925064695/0001104659-25-064695-index.htm"},{"fact_type":"executive_change","fact_key":"452b2244e9","cik":1372299,"ticker":"OCGN","company_name":"Ocugen, Inc.","filed_at":"2025-04-25T23:59:59+00:00","payload":{"action":"nominated","action_category":"appointment","departure_tone":"not_applicable","effective_date":null,"interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Blaise Coleman was appointed as Director at Ocugen, Inc..","evidence_excerpt":"The Board plans to nominate Satish Chandran, Ph.D. and Blaise Coleman for election to the Board at the 2025 Annual Meeting to replace Dr. Fernandes and Dr. Whittington.","confidence":0.85,"filing_url":"https://secwatch.observer/filing/0001104659-25-039478","anchor_url":"https://secwatch.observer/filing/0001104659-25-039478#claim-452b2244e9","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1372299/000110465925039478/0001104659-25-039478-index.htm"},{"fact_type":"executive_change","fact_key":"df1afd8b36","cik":1372299,"ticker":"OCGN","company_name":"Ocugen, Inc.","filed_at":"2025-04-25T23:59:59+00:00","payload":{"action":"nominated","action_category":"appointment","departure_tone":"not_applicable","effective_date":null,"interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Satish Chandran was appointed as Director at Ocugen, Inc..","evidence_excerpt":"The Board plans to nominate Satish Chandran, Ph.D. and Blaise Coleman for election to the Board at the 2025 Annual Meeting to replace Dr. Fernandes and Dr. Whittington.","confidence":0.85,"filing_url":"https://secwatch.observer/filing/0001104659-25-039478","anchor_url":"https://secwatch.observer/filing/0001104659-25-039478#claim-df1afd8b36","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1372299/000110465925039478/0001104659-25-039478-index.htm"},{"fact_type":"executive_change","fact_key":"7ff984e033","cik":1372299,"ticker":"OCGN","company_name":"Ocugen, Inc.","filed_at":"2025-04-25T23:59:59+00:00","payload":{"action":"not stand for re-election","action_category":"departure","departure_tone":"routine","effective_date":null,"interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":true},"claim":"Marna C. Whittington departed as Director at Ocugen, Inc..","evidence_excerpt":"Separately, on April 21, 2025, Marna C. Whittington, Ph.D., a member of the Board, the Compensation Committee of the Board, and a member and chair of the Audit Committee of the Board, informed the Company of her decision to not stand for re-election to the Board at the Company’s 2025 Annual Meeting.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-25-039478","anchor_url":"https://secwatch.observer/filing/0001104659-25-039478#claim-7ff984e033","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1372299/000110465925039478/0001104659-25-039478-index.htm"},{"fact_type":"executive_change","fact_key":"d8fab15b7c","cik":1372299,"ticker":"OCGN","company_name":"Ocugen, Inc.","filed_at":"2025-04-25T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":null,"interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":true},"claim":"Prabha Fernandes resigned as Director at Ocugen, Inc..","evidence_excerpt":"Prabha Fernandes, Ph.D., FIDSA, a member of the Board of Directors (the “Board”) of Ocugen, Inc. (the “Company”), a member and chair of the Compensation Committee of the Board, a member of the Audit Committee of the Board and the Science and Technology Committee of the Board, informed the Company that she is resigning from the Board effective at the Company’s 2025 Annual Meeting of Stockholders (the “2025 Annual Meeting”).","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-25-039478","anchor_url":"https://secwatch.observer/filing/0001104659-25-039478#claim-d8fab15b7c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1372299/000110465925039478/0001104659-25-039478-index.htm"},{"fact_type":"executive_change","fact_key":"0825cd434e","cik":1372299,"ticker":"OCGN","company_name":"Ocugen, Inc.","filed_at":"2024-11-15T23:59:59+00:00","payload":{"action":null,"action_category":"departure","departure_tone":"routine","effective_date":"2024-11-14","interim":false,"role":"principal financial officer and principal accounting officer","role_category":"cfo","successor_name":"Ramesh Ramachandran","successor_named":true},"claim":"Michael Breininger departed as principal financial officer and principal accounting officer at Ocugen, Inc..","evidence_excerpt":"Michael Breininger, the Company’s Corporate Controller, will no longer serve as the principal financial officer and principal accounting officer of the Company.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-24-119698","anchor_url":"https://secwatch.observer/filing/0001104659-24-119698#claim-0825cd434e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1372299/000110465924119698/0001104659-24-119698-index.htm"},{"fact_type":"executive_change","fact_key":"97991ee2dd","cik":1372299,"ticker":"OCGN","company_name":"Ocugen, Inc.","filed_at":"2024-11-15T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-11-14","interim":false,"role":"principal financial officer and principal accounting officer","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"Ramesh Ramachandran was appointed as principal financial officer and principal accounting officer at Ocugen, Inc..","evidence_excerpt":"the Board of Directors of Ocugen, Inc. (the “ Company ”) appointed Ramesh Ramachandran to serve as the Company’s principal financial officer and principal accounting officer","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-24-119698","anchor_url":"https://secwatch.observer/filing/0001104659-24-119698#claim-97991ee2dd","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1372299/000110465924119698/0001104659-24-119698-index.htm"},{"fact_type":"earnings_release","fact_key":"c6e54e4e456928ba59fc70e3cb677068c48154e3","cik":1372299,"ticker":"OCGN","company_name":"Ocugen, Inc.","filed_at":"2024-05-14T23:59:59+00:00","payload":{"eps_text":"a $0.05 net loss per common share","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"Total operating expenses for the three months ended March 31, 2024 were $13.2 million","period_text":"three months ended March 31, 2024","report_date":"2024-05-14","result_type":"reported_results","revenue_text":null},"claim":"Ocugen, Inc. reported three months ended March 31, 2024 results: net income Total operating expenses for the three months ended March 31, 2024 were $13.2 million, EPS a $0.05 net loss per common share.","evidence_excerpt":"Ocugen reported a $0.05 net loss per common share for the three months ended March 31, 2024 compared to a $0.08 net loss per common share for the three months ended March 31, 2023.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001628280-24-023179","anchor_url":"https://secwatch.observer/filing/0001628280-24-023179#claim-c6e54e4e456928ba59fc70e3cb677068c48154e3","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1372299/000162828024023179/0001628280-24-023179-index.htm"},{"fact_type":"earnings_release","fact_key":"8209aa53cb5483405264cc14f2fcd238dda24b90","cik":1372299,"ticker":"OCGN","company_name":"Ocugen, Inc.","filed_at":"2024-05-14T23:59:59+00:00","payload":{"eps_text":"a $0.05 net loss per common share","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"a $0.05 net loss per common share","period_text":"first quarter 2024","report_date":"2024-05-14","result_type":"reported_results","revenue_text":null},"claim":"Ocugen, Inc. reported first quarter 2024 results: net income a $0.05 net loss per common share, EPS a $0.05 net loss per common share.","evidence_excerpt":"Ocugen reported a $0.05 net loss per common share for the three months ended March 31, 2024 compared to a $0.08 net loss per common share for the three months ended March 31, 2023.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001628280-24-023179","anchor_url":"https://secwatch.observer/filing/0001628280-24-023179#claim-8209aa53cb5483405264cc14f2fcd238dda24b90","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1372299/000162828024023179/0001628280-24-023179-index.htm"},{"fact_type":"governance_change","fact_key":"abc0df4066816fdddb1fcb4ee29a49eae4f804c4","cik":1372299,"ticker":"OCGN","company_name":"Ocugen, Inc.","filed_at":"2024-05-10T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2024-05-20","item_codes_triggered":["5.03"],"summary_text":"Creation of Series C Preferred Stock with voting rights linked to Common Stock and redemption provisions"},"claim":"Ocugen, Inc.: Creation of Series C Preferred Stock with voting rights linked to Common Stock and redemption provisions (effective 2024-05-20).","evidence_excerpt":"Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. Series C Preferred Stock The board of directors (the “ Board ”) of Ocugen, Inc. (the “ Company ”) declared a dividend of one one-thousandth (1/1,000th) of a share of Series C Preferred Stock, par value $0.01 per share (“ Series C Preferred Stock ”), for each outstanding share of the Company’s common stock, par value $0.01 per share (“ Common Stock ”) to stockholders of record at 5:00 p.m. Eastern Time on May 20, 2024 (the “ Record Date ”).","confidence":0.7,"filing_url":"https://secwatch.observer/filing/0001104659-24-059907","anchor_url":"https://secwatch.observer/filing/0001104659-24-059907#claim-abc0df4066816fdddb1fcb4ee29a49eae4f804c4","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1372299/000110465924059907/0001104659-24-059907-index.htm"},{"fact_type":"earnings_release","fact_key":"bb2a36ec90f65fb5073c5f680ff1a87a54a3bcb3","cik":1372299,"ticker":"OCGN","company_name":"Ocugen, Inc.","filed_at":"2024-04-02T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the fourth quarter and the fiscal year ended December 31, 2023","report_date":"2024-04-02","result_type":"reported_results","revenue_text":null},"claim":"Ocugen, Inc. reported financial results for the fourth quarter and the fiscal year ended December 31, 2023.","evidence_excerpt":"On April 2, 2024, Ocugen, Inc. (the \"Company\") issued a press release announcing certain financial data for the fourth quarter and the fiscal year ended December 31, 2023.","confidence":0.8,"filing_url":"https://secwatch.observer/filing/0001628280-24-014236","anchor_url":"https://secwatch.observer/filing/0001628280-24-014236#claim-bb2a36ec90f65fb5073c5f680ff1a87a54a3bcb3","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1372299/000162828024014236/0001628280-24-014236-index.htm"},{"fact_type":"governance_change","fact_key":"32d4eea2f4600751b76bd0f2c0e3bcbee659b1f6","cik":1372299,"ticker":"OCGN","company_name":"Ocugen, Inc.","filed_at":"2024-03-20T23:59:59+00:00","payload":{"change_type":"bylaw_amendment","effective_date":"2024-03-15","item_codes_triggered":["5.03"],"summary_text":"Reduced the quorum requirement for stockholder meetings from a majority to one third of voting power."},"claim":"Ocugen, Inc.: Reduced the quorum requirement for stockholder meetings from a majority to one third of voting power (effective 2024-03-15).","evidence_excerpt":"On March 15, 2024, the Board of Directors of the Company approved an amendment (the “Bylaws Amendment”) to the Second Amended and Restated Bylaws of the Company (the “Bylaws”), effective immediately. The Bylaws Amendment amended Section 2.5 of ARTICLE II of the Bylaws to reduce the quorum requirement for all meetings of stockholders of the Company from a majority of the voting power of the outstanding shares of the Corporation entitled to vote generally in the election of directors to one third of the voting power of the outstanding shares of the Corporation entitled to vote generally in the election of directors.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-24-036775","anchor_url":"https://secwatch.observer/filing/0001104659-24-036775#claim-32d4eea2f4600751b76bd0f2c0e3bcbee659b1f6","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1372299/000110465924036775/0001104659-24-036775-index.htm"},{"fact_type":"executive_change","fact_key":"0f225ccff6","cik":1372299,"ticker":"OCGN","company_name":"Ocugen, Inc.","filed_at":"2024-03-20T23:59:59+00:00","payload":{"action":"will not stand for re-election","action_category":"departure","departure_tone":"routine","effective_date":null,"interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Ramesh Kumar departed as Director at Ocugen, Inc..","evidence_excerpt":"Ramesh Kumar, PhD, a member of the board of directors (the “Board of Directors”) since 2019 notified Ocugen, Inc. (the “Company”) that he will not stand for re-election as a director of the Company upon the expiration of his current term, which expires at the Company’s 2024 Annual Meeting of Stockholders (the “Annual Meeting”).","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-24-036775","anchor_url":"https://secwatch.observer/filing/0001104659-24-036775#claim-0f225ccff6","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1372299/000110465924036775/0001104659-24-036775-index.htm"}]}